In accordance with Sections 859A and 859J of the Companies Act 2006

MR01

Particulars of a charge

236495/13



	A fee is payable with this form. Please see 'How to pay' on the last page	You can use the WebFiling service to file this form online. Please go to www.companieshouse.gov.uk		
•	What this form is for You may use this form to register a charge created or evidenced by an instrument	What this form is NOT for You may not use this form to register a charge where there is no instrument. Use form MR0	For further information, please refer to our guidance at www.companieshouse gov uk	
	This form must be delivered to the Regis 21 days beginning with the day after the delivered outside of the 21 days it will be court order extending the time for delivery	LD3	*L4MY8D2Q* 24/12/2015 #55 COMPANIES HOUSE	
	You must enclose a certified copy of the scanned and placed on the public record			
1	Company details		For official use	
Company number	0 2 3 3 0 9 1 3		→ Filling in this form Please complete in typescript or in	
Company name in full	Mercury Pharma Group Limit	ced /	bold black capitals All fields are mandatory unless specified or indicated by *	
2	Charge creation date		,	
Charge creation date	$\begin{bmatrix} d_1 & d_8 & & \end{bmatrix} \begin{bmatrix} m_1 & m_2 & & \end{bmatrix} \begin{bmatrix} y_2 & y_0 \end{bmatrix}$	y 1 y 5 V		
3	Names of persons, security agents	or trustees entitled to the charge		
	Please show the names of each of the p entitled to the charge	ersons, security agents or trustees		
Name	Goldman Sachs Bank USA (th	ne "Collateral Agent")		
Name				
Name			-	
Name				
	If there are more than four names, pleas tick the statement below I confirm that there are more than for trustees entitled to the charge			

	Particulars of a charge	
4	Brief description	
	Please give a short description of any land, ship, aircraft or intellectual property registered or required to be registered in the UK subject to a charge (which is not a floating charge) or fixed security included in the instrument	Please submit only a short description if there are a number of plots of land, aircraft and/or ships, you should simply describe some
Brief description	UK Trademark Registration Numbers 2593701, 2166474, 2646631, 2648359 and the other intellectual property listed in Schedule II of the instrument whose actual owner is expressed to be Mercury	of them in the text field and add a statement along the lines of, "for more details please refer to the instrument" Please limit the description to the
	Pharma Group Limited and is registered in the UK For more details please refer to the instrument	available space
5	Other charge or fixed security	
	Does the instrument include a charge (which is not a floating charge) or fixed security over any tangible or intangible or (in Scotland) corporeal or incorporeal property not described above? Please tick the appropriate box [✓] Yes □ No	
6	Floating charge	1
	Is the instrument expressed to contain a floating charge? Please tick the appropriate box	
	☐ Yes Continue	
	[✓] No Go to Section 7	
	is the floating charge expressed to cover all the property and undertaking of the company?	
7	Yes	
	Negative Pledge	
	Do any of the terms of the charge prohibit or restrict the company from creating further security that will rank equally with or ahead of the charge? Please tick the appropriate box	
	☐ Yes [✓] No	
8	Trustee statement •	·
	You may tick the box if the company named in Section 1 is acting as trustee of the property or undertaking which is the subject of the charge	This statement may be filed after the registration of the charge (use form MR06)
9	Signature	· <u></u>
	Please sign the form here	
Signature	Signature X Allen & Overy CP x on behalf of the Collateral Agent on 21 12 12 1	:
	This form must be signed by a person with an interest in the charge	
		<u> </u>

MR01

MR01

Particulars of a charge

Presenter information	Important information
You do not have to give any contact information, but if you do, it will help Companies House if there is a query on the form. The contact information you give will be	Please note that all information on this form will appear on the public record
visible to searchers of the public record	£ How to pay
Contact name Tumise Jegede/Zhen Yang Kua Company name	A fee of £13 is payable to Companies House in respect of each mortgage or charge filed on paper
Allen & Overy LLP	. ,
Address One Bishops Square	Make cheques or postal orders payable to 'Companies House'
	Where to send
	You may return this form to any Companies House
Past town London	address However, for expediency, we advise you to return it to the appropriate address below:
County/Region	For companies registered in England and Wales
Postcode E 1 6 A D	The Registrar of Companies, Companies House, Crown Way, Cardiff, Wales, CF14 3UZ
Country United Kingdom	DX 33050 Cardiff
ха	For companies registered in Scotland
Telephone 020 3088 0000	The Registrar of Companies, Companies House, Fourth floor, Edinburgh Quay 2,
✓ Certificate	139 Fountainbridge, Edinburgh, Scotland, EH3 9FF DX ED235 Edinburgh 1
We will send your certificate to the presenter's address if given above or to the company's Registered Office if	or LP - 4 Edinburgh 2 (Legal Post)
you have left the presenter's information blank	For companies registered in Northern Ireland The Registrar of Companies, Companies House,
✓ Checklist	Second Floor, The Linenhall, 32-38 Linenhall Street, Belfast, Northern Ireland, BT2 8BG
We may return forms completed incorrectly or with information missing	DX 481 N R Belfast 1
	<i>i</i> Further information
Please make sure you have remembered the following	For further information, please see the guidance notes
The company name and number match the information held on the public Register	on the website at www companieshouse gov uk or email enquiries@companieshouse gov uk
You have included a certified copy of the instrument with this form	This form is available in an
☐ You have entered the date on which the charge	alternative format. Please visit the
was created You have shown the names of persons entitled to	forms page on the website at
the charge	www.companieshouse.gov.uk
You have ticked any appropriate boxes in Sections 3, 5, 6, 7 & 8	Titti.oompamoonoaoo.gov.ak
You have given a description in Section 4, if appropriate	
You have signed the form	
You have enclosed the correct fee Please do not send the original instrument, it must	
be a certified copy	





CERTIFICATE OF THE REGISTRATION OF A CHARGE

Company number: 2330913

Charge code: 0233 0913 0016

The Registrar of Companies for England and Wales hereby certifies that a charge dated 18th December 2015 and created by MERCURY PHARMA GROUP LIMITED was delivered pursuant to Chapter A1 Part 25 of the Companies Act 2006 on 24th December 2015

Given at Companies House, Cardiff on 7th January 2016





SUPPLEMENT NO 1 dated as of December 18, 2015 (this "Supplement"), to the Pledge and Security Agreement dated as of October 21, 2015 (as amended, restated, supplemented, waived or otherwise modified from time to time, the "Security Agreement"), among each Guarantor from time to time party thereto, Goldman Sachs Bank USA, as administrative agent (in such capacity and any successor in such capacity, the "Administrative Agent"), Goldman Sachs Bank USA, as collateral agent (in such capacity and any successor in such capacity, the "Collateral Agent") for the Secured Parties (as defined therein)

- A Reference is made to (i) the Credit and Guaranty Agreement dated as of October 21, 2015, (as amended, restated, supplemented, waived or otherwise modified from time to time, the "Credit Agreement"), among the Borrower, certain subsidiaries of the Borrower party thereto as Guarantors from time to time, the Lenders party thereto from time to time and Goldman Sachs Bank USA, as Administrative Agent and Collateral Agent and (ii) the Credit Agreement Joinder dated as of November 20, 2015 entered into by the undersigned subsidiaries (the "New Subsidiaries" and each a "New Subsidiary") as required by Section 5 11 of the Credit Agreement
- B Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement and the Security Agreement
- C The Credit Parties have entered into the Security Agreement in order to induce the Lenders to make extensions of credit under the Credit Agreement Section 5 16 of the Security Agreement provides that additional subsidiaries may become Guarantors under the Security Agreement by execution and delivery of an instrument in the form of this Supplement Each New Subsidiary is executing this Supplement in accordance with the requirements of the Credit Agreement to become a Guarantor under the Security Agreement in order to induce the Lenders to make extensions of credit (if available under the Credit Agreement) and as consideration for extensions of credit previously made under the Credit Agreement

Accordingly, the Administrative Agent, the Collateral Agent and the New Subsidiaries agree as follows

SECTION 1 In accordance with Section 5 16 of the Security Agreement, each New Subsidiary by its signature below becomes a Guarantor under the Security Agreement and agrees to be bound by all terms, covenants and conditions thereunder with the same force and effect as if originally named therein as a Guarantor and such New Subsidiary hereby (a) agrees to all the terms, covenants and provisions of the Security Agreement applicable to it as a Guarantor thereunder and (b) represents and warrants that (1) with respect to representations and warranties made by it under the Security Agreement that are not qualified by materiality, such representations and warranties are true and correct in all material respects, and (11) with respect to the representations and warranties made by it under the Security Agreement that are qualified by materiality, such representations and warranties are true and correct in all respects, in each case, on and as of the date hereof In furtherance of the foregoing, each New Subsidiary, as security for the payment and performance in full of the Obligations (as defined in the Security Agreement) when due (whether at stated maturity, by acceleration or otherwise), does hereby create, grant and pledge to the Collateral Agent, for the benefit of the Secured Parties, a security interest in and Lien on all such New Subsidiary's right, title and interest in and to the Collateral (as defined in the Security Agreement) of such New Subsidiary (in each case, however, excluding any assets, rights, property and/or interest subject to (1) any Swedish Transaction Security or (11) the security over which must be pledged and/or perfected in accordance with Swedish law) and expressly assumes all obligations and liabilities of a Guarantor under the Security Agreement Each reference to a "Guarantor" or "Credit Party" in the Secu-

SC1 3988541 5A

EXCEPT FOR MATERIAL REDACTED
PURSUANT TO SECTION 859G OF THE COMPANIES
ACT 2006 I CERTIFY THAT THIS IS A CORRECT
COPY OF THE ORIGINAL DOCUMENT

ALLEN & OVERY LLP

Allen & Overy LLP 24.12.2015 rity Agreement shall be deemed to include each New Subsidiary The Security Agreement is hereby incorporated herein by reference

SECTION 2 Each New Subsidiary represents and warrants to the Administrative Agent and the other Secured Parties that this Supplement has been duly authorized, executed and delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, subject to (i) the effects of bankruptcy, insolvency, moratorium, reorganization, fraudulent conveyance or other similar laws affecting creditors' rights generally, (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and (iii) implied covenants of good faith and fair dealing

SECTION 3 This Supplement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract This Supplement shall become effective when (a) the Collateral Agent shall have received a counterpart of this Supplement that bears the signature of each New Subsidiary and (b) the Agents have executed a counterpart hereof

SECTION 4 Each New Subsidiary hereby represents and warrants that (a) set forth on Schedule I attached hereto is a true and correct schedule of all the Pledged Equity Securities and Pledged Debt Securities of such New Subsidiary as of the date hereof, (b) to each New Subsidiary's actual knowledge, Schedule II attached hereto sets forth the Patents that are issued or the subject of a pending application and the Trademarks and Copyrights that are registered or the subject of a pending application, in each case, in the United States Patent and Trademark Office, United States Copyright Office or the equivalents thereof in any other country or jurisdiction, and, in each case, owned by such New Subsidiary as of the date hereof, (c) set forth on Schedule III attached hereto is a true and correct schedule of all Commercial Tort Claims of such New Subsidiary individually in excess of \$5,000,000 as of the date hereof, (d) set forth on Schedule IV attached hereto, is the true and correct legal name of such New Subsidiary, its jurisdiction of formation and the location of its chief executive office, (e) except as set forth in Schedule V, all Accounts of such New Subsidiary have been originated by such New Subsidiary and all Inventory has been produced or acquired by such New Subsidiary in the ordinary course of business, (f) set forth in Schedule VI is a true and complete list of all Deposit Accounts, Securities Accounts and Commodity Accounts maintained by such New Subsidiary, including the name of each institution where each such account is held, the name of each such account, the name of each entity that holds each account and to the extent any such account is an Excluded Account, stating the reason such account is an Excluded Account and (g) set forth on Schedule VII attached hereto is a true and correct schedule of all Letter of Credit Rights of such New Subsidiary relating to Letters of Credit with a face amount in excess of \$5,000,000 as of the date hereof

SECTION 5 Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect

SECTION 6. THIS SUPPLEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS SUPPLEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

SECTION 7 In the event any one or more of the provisions contained in this Supplement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and in the Security Agreement shall not in any way be affected or impaired thereby The parties shall endeavor in good-faith negotiations to replace the invalid,

illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions

SECTION 8 All communications and notices hereunder shall be in writing and given as provided in Section 5 01 of the Security Agreement

SECTION 9 Each New Subsidiary agrees to reimburse the Collateral Agent for its reasonable and documented out-of-pocket expenses in connection with this Supplement, including the reasonable and documented fees, disbursements and other charges of counsel for the Collateral Agent

[Signature pages follow]

IN WITNESS WHEREOF, the New Subsidiaries and the Agents have duly executed this Supplement to the Security Agreement as of the day and year first above written

(4522142), as a New Subsidiary,
Ву
Name JOHN BEIGHTON Title DIRECTOR
MERCURY PHARMACEUTICALS LIMITED (2619880), as a New Subsidiary,
Ву
Name JOHN BEIGHTON Title DIRECTOR
MERCURY/PHARMA (GENERICS) LIMITED (2760679), s a New Subsidiary,
Ву
Name / JOHN BELGHTON Title DIRECTOR
GIVEN UNDER THE COMMON SEAL OF AMDIPHARM LIMITED (364596) AND DELIVERED AS A DEED, as a New Subsidiary
Ву
Name Title
Ву
Name Títle

FOCUS PHARMACEUTICALS LIMITED

[Signature Page to Supplement No 1 to Pledge and Security Agreement]

IN WITNESS WHEREOF, the New Subsidiaries and the Agents have duly executed this Supplement to the Security Agreement as of the day and year first above written


Name Title: MERCURY PHARMACEUTICALS LIMITED (2619880), as a New Subsidiary, By. Name. Title MERCURY PHARMA (GENERICS) LIMITED (2760679), as a New Subsidiary,

FOCUS PHARMACEUTICALS LIMITED

(4522142), as a New Subsidiary,

By:
Name:

GIVEN UNDER THE COMMON SEAL OF AMDIPHARM LIMITED (364596) AND DELIVERED AS A DEED, as a New Subsidiary,



[Signature Page to Supplement No. 1 to Pledge and Security Agreement]

Title.

AMDIPHARM MERCURY INTERNATIONAL LIMITED (88638), as a New Subsidiary,

by.		
Name. Title	MARK WANU DIRECTOR	£52
MERCURY LIMITED	DER THE COMMO Y PHARMA INTERN (20440) VERED AS A DEED	IATIONAL
Ву		
Name [.] Title		
By.		
Name. Title.		
MERCURY LIMITED	IDER THE COMMO Y PHARMACEUTIC (325288) VERED AS A DEED	ALS (IRELAND)
Ву:		
Name: Title		
Ву:		
Name: Title		Alexandria de la compania de la comp

[Signature Page to Supplement No. 1 to Pledge and Security Agreement]

AMDIPHARM MERCURY INTERNATIONAL LIMITED (88638), as a New Subsidiary,

Ву Name Title GIVEN UNDER THE COMMON SEAL OF MERCURY PHARMA INTERNATIONAL LIMITED (20440) AND DELIVERED AS A DEED, as a New Subsidiary, Ву Name JOHN BETGHTON Title DIRECTOR Ву Name Title SELREMAKY KOHVAM GIVEN UNDER THE COMMON SEAL OF MERCURY PHARMACEUTICALS (IRELAND) LIMITED (325288) AND DELIVERED AS A DEED, as a New Subsidiary, Ву Name OHN BEIGHTON

DIRECTOR

RIBERT SULLY

COMPANY SELRETARY

[Signature Page to Supplement No 1 to Pledge and Security Agreement]

Title

Name Title

By

FOCUS PHARI (6317129), as a l		
Name: Title	JIHN	BEIGHTON
	70,	RECTOL
MERCURY PH (2330913), as a l	IARMA GROU New Subsidiery,	P LIMITED
Ву		
Name Title	JOHN B	ET GHTON
AMDIPHARM		, as a New Subsidiary,
Ву		
Name Title		
AMDIPHARM ary,	AG (109.710.39	96), as a New Subsidi-
By [.]		
Name Title		

By: Name: Title: MERCURY PHARMA GROUP LIMITED (2330913), as a New Subsidiary, By. Name: Title: AMDIPHARM BV (24341987), as a New Subsidiary, <u>Vistra</u> B.V. By: Name: Mark This. Title: Director C.E. Van den Broek RH W. Fundekotter holder B Director AMDIPHARM AG (109.710.396), as a New Subsidiагу, By: Name:

FOCUS PHARMA HOLDINGS LIMITED

(6317129), as a New Subsidiary,

Title:

FOCUS PHARMA HOLDINGS LIMITED (6317129), as a New Subsidiary,

Ву	
	Name Title:
ME (23)	RCURY PHARMA GROUP LIMITED 30913), as a New Subsidiary,
Ву:	
	Name: Title:
AM	DIPHARM BV (24341987), as a New Subsidiary,
Ву	, , , , , , , , , , , , , , , , , , , ,
	Name. Title.
AMI ary,	DIPHARM AG (109 NO.396), as a New Subsidi-
By [.]	
4	
T	Vame: itle Della TR

AMDIPHARM HOLDINGS, a société à responsabilité limitée incorporated and existing under the laws of the Grand Duchy of Luxembourg, with a share capital of EUR 127,609,000, having its registered office at 46A, avenue J.F. Kennedy, L-1855 Luxembourg and registered with the Resistre de Commerce et des Sociétés, Luxembourg under humber B 105086, as a New Subsid-Ву: Name: ABREL AHMAD Title DIRECTOR ABCUR AB (556701/3957), as a New Subsidiary, By: LOHN BEIGHTON Name DIRECTOR AMDIPHARM MERCURY LIMITED (111126), as a New Subsidiary, Ву Name ADEEL PAHMAD Title. DIRECTOR AMDIPHARM MERCURY HOLDCO LIMITED (111295), as a New Subsidiary, By:

AMDIPHARM MERCURY MIDCO LIMITED (111296), as a New Subsidiary, Ву MAKK WANLESS Name: DIRECTOR Title: AMDIPHARM MERCURY DEBTCO LIMITED (111883), as a New Subsidiary, Ву. Name: MARK WANGS Title PIRECTOR **AMDIPHARM MERCURY NEWCO LIMITED** (111713), as a New Subsidiary, Ву. Name: MAKK WANLESS Title: DIRECTOR AMDIPHARM INTERNATIONAL HOLDINGS LIMITED (88637), as a New Subsidiary, Ву MARK WANLESS Name Title PILECTOR AMDIPHARM MERCURY UK LIMITED (08169596), as a New Subsidiary,

[Signature Page to Supplement No. 1 to Pledge and Security Agreement]

By.

Name. Title.

(111296), as a New Subsidiary, Ву Name Title AMDIPHARM MERCURY DEBTCO LIMITED (111883), as a New Subsidiary, Ву Name Title AMDIPHARM MERCURY NEWCO LIMITED (111713), as a New Subsidiary, Ву Name Title. AMDIPHARM INTERNATIONAL HOLDINGS LIMITED (88637), as a New Subsidiary, Ву Name Title AMDIPHARM MERCURY UK LIMITED (08169596), as a New Subsidiary, Ву Name LJOHN BEIGHOR Tıtle DIRECTOR

AMDIPHARM MERCURY MIDCO LIMITED

AMDIPHARM MERCURY HOLDCO UK LIMITED (08189816), as a New Subsidiary,

Ву:			
	Name. Title.	JOHN BEIGHTON DIRECTOR	

[Signature Page to Supplement No. 1 to Pledge and Security Agreement]

GOLDMAN SACHS BANK USA, as Administrative Agent and Collateral Agent

By:

Name / / / / Title:

Elizabeth Fischer Authorized Signatory

[Signature Page to Supplement No 1 to Pledge and Security Agreement]

Schedule I to Supplement No 1 to the Security Agreement

Pledged Collateral of the New Subsidiary

PLEDGED EQUITY SECURITIES

Name of Issuer	Registered Owner	Number and Class of Pledged Equity Security	Number of Issuer Certificate (if applicable)	Percentage of Equity Interests
Amdıpharm B V	Amdıpharm AG	130,000 Ordinary Shares	N/A	100%
Amdıpharm AG	Amdıpharm Holdıngs	1,360,000 Registered Shares	1	100%
Mercury Pharma International Limited	Mercury Pharmaceuti- cals (Ireland) Limited	5,810,000	N/A	100%
Amdıpharm Holdıngs	Amdipharm Interna- tional Holdings Lim- ited	5,104,360 Ordinary Shares	N/A	100%
Amdipharm Mercury Midco Limited	Amdipharm Mercury Holdco Limited	14,229,916 80 Ordinary Shares	Certificate 7	100%
Amdipharm Mercury Newco Limited	Amdipharm Mercury Debtco Limited	8,865,359 80 Ordinary Shares	Certificate 7	100%
Amdipharm Mercury Debtco Limited	Amdipharm Mercury Midco Limited	13,762,486,727 80 Ordinary Shares	Certificate 8	100%
Amdipharm Mercury Limited	Concordia Investments (Jersey) Limited	1,180,877 A3 Ordinary Shares 14,058,617 A1 Ordinary Shares 405,939 A2 Ordinary Shares 900,000 B Ordinary Shares 900,000 C Ordinary Shares 1,568,000 E Ordinary Shares	Certificate 746 Certificate 729 Certificate 744 Certificate 773 Certificate 800 Certificate 809	100%
Amdıpharm Mercury Holdco Limited	Amdipharm Mercury Limited	14,229,916 80 Ordinary Shares	Certificate 6	100%
Amdipharm Interna- tional Holdings Lim- ited	Amdipharm Mercury Newco Limited	20 B Shares 198,687 Ordinary Shares	Certificate 5 Certificate 4	100%
Amdipharm Mercury International Limited	Concordia Holdings (Jersey) Limited	3 Ordinary Shares	Certificate 5	100%
Focus Pharmacueti- cals Limited	Focus Pharma Hold- ings Limited	98 Ordinary Shares	N/A	100%
Mercury Pharmaceu- ticals Limited	Mercury Pharma Group Limited	100 Shares	2	100%

Name of Issuer	Registered Owner	Number and Class of Pledged Equity Security	Number of Issuer Certificate (if applicable)	Percentage of Equity Interests
Mercury Pharma (Generics) Limited	Mercury Pharma Group Limited	2 Ordinary Shares	1	100%
Amdıpharm Limited	Amdıpharm B V	1 Ordinary Share	2	100%
Mercury Pharmaceu- ticals (Ireland) Lim- ited	Mercury Pharma Group Limited	2 Ordinary Shares	2	100%
Focus Pharma Hold- ings Limited	Mercury Pharma Group Limited	829,120 A Ordinary Shares 130,000 B Ordinary Shares 5,000 Participating Preference Shares	17 18 19	100%
Mercury Pharma Group Limited	Concordia Investment Holdings (UK) Lim- ited	36,748,824 Ordinary Shares	N/A	100%
Amdipharm Mercury UK Limited	Amdipharm Mercury Holdco UK Limited	100 Ordinary Shares	N/A	100%
Amdıpharm Mercury Holdco UK Lımıted	Amdipharm Mercury Newco Limited	20,000,001 Ordinary Shares	4	100%

PLEDGED DEBT SECURITIES

Holder	Issuer	Principal Amount	Date of Pledged Debt Security	Matunty Date
Amdipharm Mercury UK Limited	Concordia Investment Holdings (UK) Limited	£ 260,000,000 00	October 21, 2015	
Amdipharm Mercury Newco Limited	Concordia Investment Holdings (UK) Limited	£ 649,873,578 79	October 21, 2015	
Amdipharm Interna- tional Holdings Lim- ited	Concordia Holdings (Jersey) Limited	£ 209,764,441 92	October 21, 2015	October 21, 2025 (payable on demand)

PATENTS, TRADEMARKS AND COPYRIGHTS

1. Trademarks

a Amdipharm Mercury International Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
Benelux	ERYTHROCIN	54190	54190	15/07/1971	Amdıpharm International Ltd	Amdipharm Mercury Inter- national Limited
Benelux	ERYTHROCINE	359225	359225	02/05/1979	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
Benelux	FUCITHALMIC	669209	402892	11/10/1984	LEO Pharma A/S	Amdipharm Mercury Inter- national Limited
Вепевих	TERAZOSAB	0910432	0910432	10/02/2012	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
Canada	AMDIPHARM	1620117			Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
Canada	ERYPED	317682	317682	22/08/1986	Amdipharm International	Amdipharm Mercury Inter- national Limited
Canada	ERY-TAB	36434	316434	18/07/1986	Amdıpharm International Ltd	Amdipharm Mercury Inter- national Limited
Canada	ERYTHRO	114377	114377	12/06/1959	Amdipharm International	Amdipharm Mercury Inter- national Limited
Canada	ERYTHROCIN	44952	44952	28/10/1952	Amdipharm International	Amdipharm Mercury Inter- national Limited
Canada	ERYTHROMID	103137	103137	20/04/1956	Amdipharm International	Amdipharm Mercury Inter- national Limited
Canada	FUCITHALMIC	884996	551582	26/09/2001	LEO Pharma A/S	Amdipharm Mercury Inter- national Limited
Canada	FUCITHALMIC	539456	551664	27/09/2001	LEO Pharma A/S	Amdipharm Mercury Inter- national Limited
Canada	PCE	347369	347369	04/11/1988	Amdipharm International	Amdipharm Mercury Inter- national Limited
СТМ	ABCUR	12399226	12399226	21/04/2014	Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
СТМ	AMDIPHARM	3091378	3091378	11/04/2005	Amdipharm International	Amdipharm Mercury Inter- national Limited
СТМ	CONCORDIA INTERNATIONAL	14839062			Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
СТМ	CONCORDIA PHARMA	14839071			Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
СТМ	FUCITHALMIC		6349757	29/07/2008	Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
СТМ	NEO-MERCAZOLE	9451279	9451279	25/03/2011	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
СТМ	VALOID	13380795			Amdipharm Mercury In- ternational Ltd	Amdipharm Mercury Inter- national Limited
Ireland	CELEVAC	51135	51135	05/03/1951	Amdipharm International	Amdipharm Mercury Inter- national Limited
Ireland	CODIPAR FORTE	2013/02230	250475	05/12/2013	Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
Ireland	CYCLIPMORPH	220758	220758	2/3/2001	Amdipharm AG	Amdipharm Mercury Inter- national Limited
Ireland	ERYTHROCIN	55313	55313	23/12/1952	Amdipharm International	Amdipharm Mercury Inter- national Limited
Ireland	ERYTHROPED	71446	71446	07/04/1967	Amdipharm International	Amdipharm Mercury Inter- national Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
Ireland	FUCITHALMIC		114610	22/03/1985	LEO Pharma A/S	Amdipharm Mercury Inter- national Limited
Ireland	GENTICIN	70822	70822	14/09/1966	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
Ireland	GENTISONE	230299	230299	12/08/2004	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
Ireland	HYTRIN	110835	110835	14/11/1983	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
Ireland	MAXOLON	73785	73785	19/08/1968	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
Ireland	VALOID	68560	68560	25/09/1964	Amdıpharm AG	Amdipharm Mercury Inter- national Limited
Sweden	SINALFA	257876	257876	06/05/1994	Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
Switzerland	ERYTHROCIN	00129/1993	403378	14/07/1993	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
Switzerland	HYTRIN	06711/1983	P-327961		Amdipharm International	Amdipharm Mercury Inter- national Limited
Switzerland	NEO-MERCAZOLE	09646/1993	P-413628	28/11/1994	Amdıpharm AG	Amdipharm Mercury Inter- national Limited
Switzerland	PEDIAMYCIN	03170/1974	2P-271510	13/01/2015	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
United Kingdom	AMDIPHARM	2311980	2311980	14/03/2003	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
United Kingdom	AMDIPHARM Logo	2656978	2656978	06/09/2013	Amdıpharm İnternational Ltd	Amdipharm Mercury Inter- national Limited
United Kingdom	ANANDAR	3043500	3043500	06/06/2014	Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
United Kingdom	BARATOL		780353	30/07/1958	Amdipharm International	Amdipharm Mercury Inter- national Limited
United Kingdom	CELEVAC		690125	22/06/1950	Amdipharm International	Amdipharm Mercury Inter- national Limited
United Kingdom	CHEMYDUR	2636804	2636804	11/01/2013	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
United Kingdom	CONCORDIA INTERNATIONAL	3138264			Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
United Kingdom	CONCORDIA PHARMA	3138265			Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
United Kingdom	CORTISTAB	732900	732900	18/01/1955	Amdipharm International	Amdipharm Mercury Inter- national Limited
United Kingdom	CYCLIMORPH	873305	873305	17/12/1964	Amdıpharm AG	Amdipharm Mercury Inter- national Limited
United Kingdom	DELTASTAB	744289	744289	12/07/1955	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
United Kingdom	DETRUNORM	2023540	2023540	21/06/1996	Amdıpharm AG	Amdipharm Mercury Inter- national Limited
United Kingdom	EFCORTESOL	3032816	3032816	07/03/2014	Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
United Kingdom	ERYTHROCIN		714134	20/01/1953	Amdipharm International	Amdipharm Mercury Inter- national Limited
United Kingdom	ERYTHROPED	 	2564998	18/02/2011	Amdipharm International	Amdipharm Mercury Inter- national Limited
United Kingdom	FUCITHALMIC		1233802	17/01/1985	Amdipharm Mercury In- ternational Limited	Amdipharm Mercury Inter- national Limited
United Kingdom	GENTICIN	892307	892307	22/03/1966	Amdipharm International	Amdipharm Mercury Inter- national Limited
United Kingdom	GENTISONE	916890	916890	07/11/1967	Amdipharm International	Amdipharm Mercury Inter- national Limited
United Kingdom	HORMONIN		1175147	18/05/1982	Amdipharm International	Amdipharm Mercury Inter- national Limited
United Kingdom	HYDROCORTISTAB		2564871	18/02/2011	Amdipharm International Ltd	Amdipharm Mercury Inter- national Limited
United	HYTRIN	 	1207588	21/11/1983	Amdipharm International	Amdipharm Mercury Inter-

Country	Trademark	Application No.	Registration	Date of Regis- tration	Registered Owner	Actual Owner
United	JANILA	3032818	3032818	07/03/2014	Amdipharm Mercury In-	Amdipharm Mercury Inter-
Kıngdom					ternational Limited	national Limited
United	JEDEVA	3043501	3043501	23/05/2014	Amdıpharm Mercury In-	Amdipharm Mercury Inter-
Kingdom					ternational Limited	national Limited
United	JENAPRI	3032819	3032819	07/03/2014	Amdipharm Mercury In-	Amdipharm Mercury Inter-
Kingdom					ternational Limited	national Limited
United	MAXALON SR		1273999	11/11/1988	Amdipharm International	Amdipharm Mercury Inter-
Kingdom					Ltd	national Limited
United	MAXOLON		814154	01/12/1960	Amdipharm International	Amdipharm Mercury Inter-
Kingdom	l .		<u></u>	<u> </u>	<u></u>	national Limited
United	NADISKA	3042049	3042049	23/05/2014	Amdipharm Mercury In-	Amdipharm Mercury Inter-
Kingdom				<u></u>	ternational Limited	national Limited
United	NEOMERCAZOLE	755595	755595	11/07/1956	Amdıpharm AG	Amdipharm Mercury Inter-
Kıngdom			<u> </u>	<u> </u>		national Limited
United	NIPATRA	2652481	2652481	15/02/2013	Amdipharm International	Amdipharm Mercury Inter-
Kingdom	ļ		<u></u>		Ltd	national Limited
United	OZBULAN	3043503	3043503	23/05/2014	Amdıpharm Mercury In-	Amdipharm Mercury Inter-
Kingdom					ternational Limited	national Limited
United	PEVANTI	3042047	3042047	23/05/2014	Amdipharm Mercury In-	Amdipharm Mercury Inter-
Kingdom				<u> </u>	ternational Limited	national Limited
United	PREDNESOL	3032817	3032817	07/03/2014	Amdipharm Mercury In-	Amdipharm Mercury Inter-
Kingdom					ternational Limited	national Limited
United	SITUKA	3013998	3013998	11/11/2013	Amdipharm International	Amdipharm Mercury Inter-
Kingdom			<u> </u>		Ltd	national Limited
United	TINETTI	3042046	3042046	23/05/2014	Amdipharm Mercury In-	Amdipharm Mercury Inter- national Limited
Kingdom			1-2	211121121	ternational Limited	
United	TOPICYCLINE		1069020	04/10/1976	Amdipharm International	Amdipharm Mercury Inter- national Limited
Kingdom				22/06/2006	Ltd Amdipharm International	Amdipharm Mercury Inter-
United	TRAMULIEF	2411500	2411500	23/06/2006	Ltd	national Limited
Kingdom			2042504	23/05/2014	Amdipharm Mercury In-	Amdipharm Mercury Inter-
United	TORSKO	3043504	3043504	23/03/2014	ternational Limited	national Limited
Kıngdom			786450	23/01/1959	Amdipharm International	Amdipharm Mercury Inter-
United	VALOID		/80430	23/01/1939	Ltd	national Limited
Kingdom	27434117	2014006	3014006	11/10/2013	Amdipharm International	Amdipharm Mercury Inter-
United	VAMJU	3014006	D014000	11/10/2013	Ltd	national Limited
Kingdom	A MINIETONI	246457	246457	10/08/1961	Amdipharm AG	Amdipharm Mercury Inter-
WIPO	AKINETON	240437	K40431	10/00/1701	randpiwiti AO	national Limited
WIDO	EDVDED	469 473 A	469 473 A	28/04/2002	Amdipharm AG	Amdipharm Mercury Inter-
WIPO	ERYPED	H09 4/3 A	HU2 4/3 M	2010412002	randpiani AO	national Limited

b Mercury Pharma Group Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
WIPO	DYAZIDE Device	516429	516429	21/09/1987	Goldshield Group plc	Mercury Pharma Group Limited
Benelux	FURABID	61421	0440209	30/12/1987	Goldshield Group plc	Mercury Pharma Group Limited
Benelux	FURADANTIN	3396	27035	29/04/1971	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Benelux	FURADANTINE	44252	367570	22/08/1980	Goldshield Group plc	Mercury Pharma Group Limited
Benelux	MACROBID	50458	393155	20/01/1984	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Benelux	MACRODANTIN	3392	27031	29/04/1971	Goldshield Group plc	Mercury Pharma Group Lamited
Benelux	PARNATE	651704	382381	28/07/1982	Goldshield Group plc	Mercury Pharma Group Limited
CTM	ARAKSHA	6444211	6444211	06/08/09	Mercury Pharma Group Lamited	Mercury Pharma Group Limited

Country	Trademark	Application No	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
СТМ	BUFECAINE	5006804	5006804	16/02/10	Mercury Pharma Group Limited	Mercury Pharma Group Limited
СТМ	CARDIOPRESSIN	4845641	4845641	01/07/09	Mercury Pharma Group Limited	Mercury Pharma Group Limited
СТМ	COBULEVE	8606758	8606758	08/06/10	Mercury Pharma Group	Mercury Pharma Group Limited
СТМ	ECONAC	1835859	1835859	28/03/03		Mercury Pharma Group
СТМ	MERCURY PHARMA	010152486	010152486	07/12/11	Mercury Pharma Group Limited	Mercury Pharma Group
СТМ	MERCURY PHARMA + WINGS LOGO	010925428	010925428	19/09/12	Mercury Pharma Group Limited	Mercury Pharma Group Limited
СТМ	OLENA	011182938	011182938	14/01/13	Mercury Pharma Group Limited	Mercury Pharma Group Limited
СТМ	ZAPAIN	4109071	4109071	10/12/09	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Ireland	ALERSOL	2013/00060	248334	11/01/2013		Mercury Pharma Group Limited
Ireland	BUFYL	2010/02132	244696	31/08/2011	Goldshield Group Limited	
Ireland	CODIPAR	2011/02136	246690	08/12/2011	Goldshield Group Ltd	Mercury Pharma Group Limited
Ireland	CYTACON	Ireland	243048	10/11/2010	Goldshield Group Ltd	Mercury Pharma Group
Ireland	DYAZIDE		82535	20/07/1973	Goldshield Group plc	Mercury Pharma Group Limited
Ireland	DYSPAMET	21311984	111670	18/07/1984	Goldshield Group plc	Mercury Pharma Group
Ireland	ELTROXIN	2012/00010	252725	03/01/2012	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Ireland	FURADANTIN	59847	59847	25/11/1957	Goldshield Group plc	Mercury Pharma Group Limited
Ireland	INFADROPS	150280	150280	31/12/1992	Goldshield Group plc	Mercury Pharma Group
Ireland	LOMOTIL	61933	61933	04/01/1960	Goldshield Group Ltd	Mercury Pharma Group Limited
Ireland	MACROBID	2010/00203	243044	10/11/2010	Goldshield Group Ltd	Mercury Pharma Group Limited
Ireland	MACRODANTIN	81156	81156	15/11/1972	Goldshield Group plc	Mercury Pharma Group Limited
Ireland	MERCURY PHARMA	2011/02223	246709	21/12/2011	Goldshield Group Ltd	Mercury Pharma Group
Ireland	PARNATE	61877	61877	16/12/1959	Goldshield Group plc	Mercury Pharma Group Limited
Ireland	PHORPAIN	246238	246238	19/10/2011	Goldshield Group Limited	
Ireland	STELAZINE	236900	236900	11/06/07	Goldshield Group Ltd	Mercury Pharma Group Limited
lreland	TRAXAM	123292	123292	25/03/87	Goldshield Group Ltd	Mercury Pharma Group Limited
Switzerland	FURADANTIN	63403/2010	611246	02/02/2011	Goldshield Group Ltd	Mercury Pharma Group
Switzerland	FURADANTINE	01426/1984	331406	26/06/1984	Goldshield Group plc	Limited Mercury Pharma Group
Switzerland	MACROBID	06285/1984	335970	22/01/1985	Goldshield Group plc	Limited Mercury Pharma Group
Switzerland	MACRODANTIN	01419/1989	371037	20/07/1989	Goldshield Group plc	Limited Mercury Pharma Group
United	ACEZO	2593701	2593701	16/12/2011	Mercury Pharma Group Limited	Limited Mercury Pharma Group Limited
Kingdom United Kingdom	ACUMEN	2166474	2166474	06/11/1998	Mercury Pharma Group	Mercury Pharma Group Limited
Kingdom United Kingdom	ALERSOL	2646631	2646631	20/12/2012	Mercury Pharma Group Limited	Mercury Pharma Group Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
United Kingdom	AMDIPHARM MERCURY	2648359	2648359	11/01/2013	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	AUREOCORT	2589540	2589540	28/10/2011	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	BUFECAINE	2544907	2544907	05/11/2010	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	BUFYL	2566538	2566538	04/03/2011	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	CHLOROMYTOL	2510953	2510953	28/08/2009	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	CODIPAR	2264280	2264280	31/08/2001	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	COPAIN	2521741	2521741	06/11/2009	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	CYNORAL	2227635	2227635	08/12/2000	Mercury Pharma Group Limited	Mercury Pharma Group Lamited
United Kingdom	CYTACON	692526	692526	Not displayed	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	DIBENYLINE	2169983	2169983	25/02/2000	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	DICLOFAST	2150095	2150095	16/10/1998	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	DINDEVAN	705824	705824		Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	DYAZIDE	2153687	2153687	05/06/1998	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	DYOBET	2640686	2640686	02/11/2012	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	DYSPAMET	1223970	1223970	21/07/1984	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	ECOPACE	2055276	2055276	04/10/1996	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	ELTROXIN	730598	730598		Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	FENBID	2169984	2169984	04/12/1998	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	FENBIMAX	2173354	2173354	06/08/1999	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	FENTAZIN	2604263	2604263	30/03/2012	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	FERSADAY	932971	932971	Not displayed	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	FERSAMAL	764725	764725		Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	FORTIPINE	2069983	2069983	08/11/1996	Goldshield Pharmaceuti- cals Limited (Goldshield Group Limited subsidiary)	Mercury Pharma Group Lamated
United Kingdom	FURADANTIN	721409	721409	01/09/1953	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	LOMOTIL	797008	797008	26/10/1959	Mercury Pharma Group Lamited	Mercury Pharma Group Limited
United Kingdom	MACROBID	1226268	1226268	12/09/1984	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	MACRODANTIN	930768	930768	11/09/1968	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	MAREVAN	761952	761952	Not displayed	Mercury Pharma Group Limited	Mercury Pharma Group Lamited
United Kingdom	MERCURY PHARMA	2589227	2589227	23/12/2011	Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	MERCURY PHARMA + LOGO	2607350	2607350	20/04/2012	Mercury Pharma Group	Mercury Pharma Group Limited
United Kingdom	MOXAID	3010658	3010658	27/09/2013	Mercury Pharma Group Limited	Mercury Pharma Group Limited

Country	Trademark	Application No.	Registration No	Date of Regis- tration	Registered Owner	Actual Owner
United Kingdom	NAVISPARE	1217827	1217827		Mercury Pharma Group Limited	Mercury Pharma Group Limited
United Kingdom	NEO-NACLEX	2470416	2470416	24/10/2007	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Jmted Kingdom	NIFOPRESS	2019815	2019815	16/02/1996	Mercury Pharma Group	Mercury Pharma Group Limited
Jnited Gingdom	OLENA	2634383	2634383	21/12/2012	Mercury Pharma Group Lamited	Mercury Pharma Group Limited
Jnited Gingdom	PARNATE	798861	798861	07/12/1959	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Jnited Kingdom	PHOR PAIN (series of 3)	2202935	2202935	22/12/2000		Mercury Pharma Group
Jinited Kingdom	ROFECAINE	2554959	2554959	05/11/2010	Goldshield Group plc	Mercury Pharma Group Lamited
United Kingdom	ROPICAINE	2554943	2554943	05/11/2010	Goldshield Group plc	Mercury Pharma Group Limited
Jnited Kingdom	SAVATA	2593838	2593838	16/12/2011	Limited	Mercury Pharma Group Limited
Jnited Kingdom	SILCHEW	2645334	2645334	07/12/2012	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Jnited Kingdom	STELAZINE	772994	772994	09/01/1958	Goldshield Group plc	Mercury Pharma Group Limited
Jnited Kingdom	TEROMEG	2612512	2612512	01/06/2012	Mercury Pharma Group Lamited	Mercury Pharma Group Limited
Jnited Kingdom	TERTROXIN	1132354	1132354		Mercury Pharma Group Lamited	Mercury Pharma Group Limited
Jnited Kingdom	TRASIDREX	1037703	1037703		Mercury Pharma Group Lamited	Mercury Pharma Group Lamited
Jnited Kingdom	TRAXAM	1302918	1302918		Mercury Pharma Group Limited	Mercury Pharma Group Limited
Jnited Gingdom	TRIPTAFEN	866008	866008		Limited	Mercury Pharma Group Limited
Jnited Kingdom	VENAXX	2543336	2543336	13/08/2010	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Jnited Kingdom	ZAPAIN	2173871	2173871	23/04/1999	Mercury Pharma Group Limited	Mercury Pharma Group Limited
Jnited Kingdom	ZYOMET	2157479	2157479	14/08/1998	Mercury Pharma Group Limited	Mercury Pharma Group Limited
VIPO	CARDIOPRESSIN	908730	908730		Goldshield Group plc	Mercury Pharma Group
VIPO	FENBID	481011A	481011A	21/11/1983	Goldshield Group Limited	Mercury Pharma Group Limited

c Focus Pharmaceuticals Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
United Kingdom	ADACIUM	2401302	2401302	1	Focus Pharmaceuticals Limited	Focus Pharmaceuticals Limited
United Kingdom	ADANIF	2401301	2401301	03/03/2006	Focus Pharmaceuticals Limited	Focus Pharmaceuticals Limited
Jnited Kingdom	ALFATRAL	2346709	2346709	1 '	Focus Pharmaceuticals Limited	Focus Pharmaceuticals Limited
Jnited Kingdom	BENZYFLAM	2377376	2377376	1 -	Focus Pharmaceuticals Limited	Focus Pharmaceuticals Limited
Jnited (ingdom	CLOMOVATE	2423279	2423279		Focus Pharmaceuticals Limited	Focus Pharmaceuticals Limited
Jnited Ungdom	ERIVEX	2616573			Focus Pharmaceuticals Limited	Focus Pharmaceuticals Limited
Jnited Gingdom	FOBRUPRO	2644763	2644763	1	Focus Pharmaceuticals Limited	Focus Pharmaceuticals Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
United	FOCAMOL	2644523	2644523	08/03/2013	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom]			l	Limited	Limited
United	FOCATIN	2644553	2644553	08/03/2013	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom		l		<u> </u>	Limited	Limited
United	FOCAZIN	2644761	2644761	08/03/2013	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom					Limited	Limited
United	FOCUS PHARMA	3046437	3046437	27/06/2014	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom				l	Limited	Limited
United	FOCUS	2377377	2377377	08/04/2005	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom	PHARMACEUTICALS				Limited	Limited
United	FOXYNIN	2644767	2644767	08/03/2013	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom	1				Lamited	Limited
United	GLIDIA	2616577	2616577	13/07/2012	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom					Limited	Limited
United	MALYCE	2423348	2423348	10/11/2006	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom					Limited	Limited
United	MEMEXO	2616575	2616575	13/07/2012	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom	ļ.				Limited	Limited
United	METMAX	2377374	2377374	08/04/2005	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom		j			Limited	Limited
United	NOLYCE	2377375	2377375	08/04/2005	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom			J		Limited	Limited
United	OROEZE	2423280	2423280	08/12/2006	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom			J		Limited	Limited
United	SERTRATAB	2346710	2346710	26/03/2004	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom					Limited	Limited
United	STERI-HALE	2346703	2346703	25/06/2004	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom					Limited	Limited
United	STERI-RESP	2346705	2346705	25/06/2004	Focus Pharmaceuticals	Focus Pharmaceuticals
Kıngdom			<u> </u>		Limited	Limited
United	TRIPRIL	2346712	2346712	26/03/2004	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom		<u> </u>			Limited	Limited
United	VOLEZE	2423278	2423278	08/12/2006	Focus Pharmaceuticals	Focus Pharmaceuticals
Kingdom	1				Limited	Limited

d Mercury Pharma International Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
Ireland	a (solid)	79874	79874	28/10/1971	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited
Ireland	AGELAN	68242	68242	09/03/1965	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited
United Kingdom	ANTIGEN	1508422	1508422	31/07/1998	Mercury Pharma Interna- tional Limited	Mercury Pharma Interna- tional Limited
lreland	CODANT	149155	149155	26/05/1992	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited
Ireland	GENOXEN	116916	116916	20/06/1985	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited
Ireland	LUBORANT	114889	114889	12/04/1985	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited
lreland	MUCOGEN	115742	115742	21/05/1985	Antigen Pharmaceuticals	Mercury Pharma Interna- tional Limited
Ireland	ORAMOX	127256	127256	11/04/1988	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited
Ireland	PONALGIC	121553	121553	08/12/1986	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited
lreland	SUREAMP/SURE AMP/SURE-AMP (Se- ries of 3)	145901	145901	15/07/1991	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited
United Kingdom	a	1175118	1175118	17/05/1982	Antigen Pharmaceuticals Limited	Mercury Pharma Interna- tional Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
United	LUBORANT	1239829	1239829	15/04/1985	Antigen Pharmaceuticals	Mercury Pharma Interna-
Kingdom					Limited	tional Limited
United	SUREAMP / SURE	1471124	1471124	07/08/1992	Antigen International	Mercury Pharma Interna-
Kingdom	AMP /	}	,		Limited	tional Limited

e Amdipharm Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
СТМ	AMDIPHARM logo	011337375	011337375	13/12/2012	Amdipharm Limited	Amdipharm Limited
WIPO	AMDIPHARM	798943	798943	14/03/2003	Amdipharm Limited	Amdıpharm Limited

f Mercury Pharmaceuticals (Ireland) Limited

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
Ireland	WARFANT	169300	169300	-	,	Mercury Pharmaceuticals
					(Ireland) Limited	(Ireland) Limited

g Abcur AB

Country	Trademark	Application No.	Registration No.	Date of Regis- tration	Registered Owner	Actual Owner
Sweden	EASYGONE	2008/06306		21/11/2008	Abcur AB	Abcur AB
Sweden	PENTOCUR	2012/03686	507526		Amdıpharm Mercury Company	Abeur AB

2. Designs

a Mercury Pharma Group Limited

Country	Design	Date of Application	Registration No.	Next Renewal Due	Registered Owner	Actual Owner
European Union	Packaging	07/02/2012	1988114 0001	07/02/2017	Mercury Pharma Group Limited	Mercury Pharma Group Limited
European Union	Packaging	07/02/2012	1988114 0002	07/02/2017	Mercury Pharma Group Limited	Mercury Pharma Group Limited
European Union	Packaging	07/02/2012	1988114 0003	07/02/2017	Mercury Pharma Group Limited	Mercury Pharma Group Limited
European Union	Packaging	07/02/2012	1988114 0004	07/02/2017	Mercury Pharma Group Limited	Mercury Pharma Group Limited
European Union	Packaging	07/02/2012	1988114 0005	07/02/2017	Mercury Pharma Group	Mercury Pharma Group Limited
European Union	Packaging	07/02/2012	1988114 0006	07/02/2017	Mercury Pharma Group Limited	Mercury Pharma Group Limited
European Union	Packaging	07/02/2012	1988114 0007	07/02/2017	Mercury Pharma Group Limited	Mercury Pharma Group Lamited
European Union	Wings Logo	07/02/2012	1989229 0001	09/02/2017	Mercury Pharma Group Limited	Mercury Pharma Group Limited

b Amdipharm Mercury International Limited

Country	Design	Date of Ap- plication	Registration No.	Next Renewal Due	Registered Owner	Actual Owner
European Union	AMCo Logo	18/03/2013	2204552 001			Amdipharm Mercury Inter- national Limited

3. Patents

Country	Patent Name/Application	Application Filing Date/Date Issued	Application Num- ber/Registration Number	Registered Owner	Actual Owner
USA	Opthalmic gel composi- tion and method of treat- ing eye infections	07/02/2012	US 6,255,299		Amdipharm Mercury Interna- uonal Limited

Schedule III to Supplement No 1 to the Security Agreement

COMMERCIAL TORT CLAIMS

None

Schedule III-1

SC1 3988541 5A

LEGAL NAME, JURISDICTION OF FORMATION AND ADDRESS

- Amdipharm B V, incorporated under the laws of the Netherlands, Schiphol Boulevard 231, 1118 BH Schiphol, The Netherlands
- 2 Amdipharm AG, incorporated under the laws of Switzerland, Gartenstrasse 22, 4052 Basel, Switzerland
- 3 Amdipharm Limited, a limited liability company incorporated in Ireland having registered number 364596 with its registered address at 3 Burlington Road, Dublin 4, Ireland
- 4 Mercury Pharma International Limited, a limited liability company incorporated in Ireland having registered number 20440 with its registered address at 4045 Kingswood Road, City West Business Park, County Dublin, Ireland
- Mercury Pharmaceuticals (Ireland) Limited, a limited liability company incorporated in Ireland having registered number 325288 with its registered address at 4045 Kingswood Road, City West Business Park, County Dublin, Ireland
- 6 Amdipharm Holdings, a company incorporated under the laws of the Grand-Duchy of Luxembourg and having its registered office at 46A, Avenue J F Kennedy, L-1855 Luxembourg, Grand-Duchy of Luxembourg
- 7 Amdipharm Mercury Limited, a company incorporated under the laws of Jersey with its registered address at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH
- Amdipharm Mercury International Limited, a company incorporated under the laws of Jersey with its registered address at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH
- 9 Amdipharm Mercury Holdco Limited, a company incorporated under the laws of Jersey with its registered address at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH
- 10 Amdipharm Mercury Midco Limited, a company incorporated under the laws of Jersey with its registered address at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH
- 11 Amdipharm Mercury Debtco Limited, a company incorporated under the laws of Jersey with its registered address at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH
- 12 Amdipharm Mercury Newco Limited, a company incorporated under the laws of Jersey with its registered address at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH
- 13 Amdipharm International Holdings Limited, a company incorporated under the laws of Jersey with its registered address at 11-15 Seaton Place, St. Helier, Jersey, JE4 0QH

Schedule IV-1

SC1 3988541 5A

- 14 Mercury Pharma Group Limited, a company incorporated under the laws of England and Wales with its registered address at Capital House, 85 King William Street, London, England, EC4N 7BL
- 15 Focus Pharma Holdings Limited, a company incorporated under the laws of England and Wales with its registered address at Capital House, 85 King William Street, London, England, EC4N 7BL
- 16 Focus Pharmaceuticals Limited, a company incorporated under the laws of England and Wales with its registered address at Capital House, 85 King William Street, London, England, EC4N 7BL
- 17 Mercury Pharma (Generics) Limited, a company incorporated under the laws of England and Wales with its registered address at Capital House, 85 King William Street, London, England, EC4N 7BL
- 18 Mercury Pharmaceuticals Limited, a company incorporated under the laws of England and Wales with its registered address at Capital House, 85 King William Street, London, England, EC4N 7BL
- 19 Amdipharm Mercury UK Limited, a company incorporated under the laws of England and Wales with its registered address at Capital House, 85 King William Street, London, England, EC4N 7BL
- 20 Amdipharm Mercury Holdco UK Limited, a company incorporated under the laws of England and Wales with its registered address at Capital House, 85 King William Street, London, England, EC4N 7BL
- 21 Abour AB, a company incorporated under the laws of Sweden with its registered office at Box 1452, 25114 Helsingborg, Sweden

Schedule V to Supplement No 1 to the Security Agreement

MATTERS RELATING TO ACCOUNTS AND INVENTORY

None

Schedule V-1

SC1 3988541 5A

DEPOSIT ACCOUNTS, SECURITIES ACCOUNTS AND COMMODITY ACCOUNTS

Entity	Financial Institution and Address	Type of Account	Account Number
Amdıpharm Mercury	Lloyds Bank International	GBP Money Market	9201*
Limited	Limited PO Box 10	Call Account EUR Money Market Call Account	9202*
	9 Broad Street St Helier, Jersey JE4 8NG	USD Money Market Call Account	9203*
Amdipharm Mercury Midco Limited	Lloyds Bank International Limited	GBP Money Market Call Account	1901*
	PO Box 10 9 Broad Street	EUR Money Market Call Account	1902*
	St Helier, Jersey JE4 8NG	USD Money Market Call Account	1903*
Amdipharm Mercury Holdco Limited	Lloyds Bank International Limited	GBP Money Market Call Account	0201*
	PO Box 10 9 Broad Street	EUR Money Market Call Account	0202*
	St Helier, Jersey JE4 8NG	USD Money Market Call Account	0203*
Amdipharm Mercury Debtco Limited	Lloyds Bank International Limited	GBP Money Market Call Account	3601*
	PO Box 10 9 Broad Street	EUR Money Market Call Account	3602*
	St Helier, Jersey JE4 8NG	USD Money Market Call Account	3603*
Amdipharm Mercury Newco Limited	Lloyds Bank International Limited	GBP Money Market Call Account	5001*
	PO Box 10 9 Broad Street	EUR Money Market Call Account	5002*
	St Helier, Jersey JE4 8NG	USD Money Market Call Account	5003*
Focus Pharmaceuti- cals Limited	National Westminster Bank	GBP	9659*
	35 Fishergate	GBP	4935
	Preston, Lancashire, United Kingdom	GBP	9667*

•	PR1 3BH	EUR	2734*
		USD	2742*
Mercury Pharmaceuticals Limited	ABSA Bank Ltd	ZAR	6799*
	Protea Park, Sandton City Johannesburg South Africa		
	National Westminster Bank	GBP	1 5185
	Piccadilly Circus Branch, Shaftsbury United Kingdom	EUR	7548*
	Cinica Magaoni	DKK	3708*
		NOK	3716*
		SEK	4267*
		GBP	9129*
		AUD	5605*
		ZAR	5621*
		ILS	2446*
		USD	7458*
		NZD	5613*
		GBP	1167*
	Ulster Bank Ireland Limited	EUR	7016*
	College Green Branch, 33,		

	Dublin 2, Ireland		
	Banco Santander S A	EUR	0924*
	Santander Operaciones Retail, Comple, 28232 Las Rozas (Madrid), Spain,		
	Banco Santander Totta	EUR	2010*
	Gestora de Negcios - Rua Augusta,, Rua Augusta, 237á 1100-051 Lisboa, Portugal		
Mercury Pharma (Generics) Limited	National Westminster Bank	GBP	9272
	Piccadilly Circus Branch, Shaftsbury United Kingdom		
Amdipharm Limited	Ulster Bank Ireland Limited	EUR	3021*
	Walkinstown Cross, Dublin 12, Ireland, Ireland	USD	0802*
	HSBC Bank PLC	EUR	8748*
	1 Grand Canal Square, Dub- lin 2, Ireland	AUD	3201*
		CHF	2213*
		MXN	8922*
		NOK	9009*
		GBP	0913*
	<u> </u>	<u> </u>	<u> </u>

		USD	0516*
		DKK	8128*
		SEK	8136*
		NZD	8179*
		PLN	8431*
		JPY	8788*
		ZAR	7875*
	National Westminster Bank	GBP	1698*
	Piccadilly Circus Branch,		
	Shaftsbury, United Kingdom		
Amdipharm Mercury International Limited	RBSI	GBP	5363*
	POBox 11,16 Library Place,St Helier, Jersey, Jer-	GBP	1244*
	sey	DKK	1244*
		EUR	1244*
Mercury Pharma	Ulster Bank Ireland Limited	EUR	0083*
International Limited			
	College Green Branch, 33, Dublin 2, Ireland		
	National Westminster Bank	GBP	3956*

	Piccadilly Circus Branch,	EUR	8978*
	Shaftsbury		
	United Kingdom		
A.J. 1	HEDG D1- DLC	CHE	(001*
Amdıpharm AG	HSBC Bank PLC	CHF	6001*
	Bederstrasse 49, PO Box 1818, Zurich, Switzerland CH-8027		
Mercury Pharmaceu- ticals (Ireland) Lim-	National Westminster Bank	GBP	7920*
ited	Piccadilly Circus Branch, Shaftsbury, United Kingdom, United Kingdom		
	Ulster Bank Ireland Limited	EUR	5099*
	College Green Branch, 33, Dublin 2, Ireland		
Amdipharm Holdings	BGL BNP PARIBAS S A	EUR	0000*
	50, Avenue J F Kennedy L 2951, Luxembourg		
Amdipharm Interna- tional Holdings Lim- ited	RBSI	GBP	1236*
ned	POBox 11,16 Library Place,St Helier, Jersey,	GBP	9152*
		GBP	5223*
		CHF	1236*
		USD	1236*
		EUR	1236*
	<u> </u>		<u> </u>

Mercury Pharma Group Limited	National Westminster Bank	EUR	1060*
	Piccadilly Circus Branch,Shaftsbury, United Kingdom	GBP	6758*
		USD	5001*
		GBP	3679*
Amdipharm Mercury UK Limited	Lloyds TSB Bank plc	GBP	7907*
	39 Threadneedle Street London, United Kingdom		
Abcur AB	Commercial Bank	EUR	2509*
	6751 Helsingborg Stortorget	NOK	2479*
		SEK	8478*
		DKK	6549*
		SEK	8788*
		CHF	1399*

^{*}Indicates an Excluded Account The average daily balance of the funds maintained on deposit therein does not exceed \$5,000,000

Schedule VII to Supplement No 1 to the Security Agreement

LETTER OF CREDIT RIGHTS

None